Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.
1. A crystalline Compound (I):
Which has an X-ray powder diffraction pattern comprising peaks at 8.6, 15.3, 22.7, and 28.1±0.2° 2θ.
2. The crystalline Compound (I) of claim 1 , which has an X-ray powder diffraction pattern as shown in FIG. 11 .
3. The crystalline Compound (I) of claim 1 , which has a DSC endotherm at about 176.2° C.
4. The crystalline Compound (I) of claim 1 , wherein the crystalline Compound (I) comprises less than 10% by weight of any other crystalline Compound (I).
5. The crystalline Compound (I) of claim 4 , wherein the crystalline Compound (I) comprises less than 5% by weight of any other crystalline Compound (I).
6. The crystalline Compound (I) of claim 1 , wherein the crystalline Compound (I) comprises less than 10% by weight of amorphous Compound (I).
7. The crystalline Compound (I) of claim 6 , wherein the crystalline Compound (I) comprises less than 5% by weight of amorphous Compound (I).
8. The crystalline Compound (I) of claim 1 , wherein the crystalline Compound (I) comprises less than 100 ppm of a compound of Formula (II):
as determined by GC/MS.
9. The crystalline Compound (I) of claim 8 , wherein the crystalline Compound (I) comprises less than 50 ppm of a compound of Formula (II) as determined by GC/MS.
10. The crystalline Compound (I) of claim 1 , wherein the crystalline Compound (I) is at least 99.5% pure as measured by HPLC.
11. A pharmaceutical composition comprising a crystalline Compound (I) of claim 1 .
12. A method of treating anemia, comprising administering a pharmaceutical composition comprising an effective amount of a crystalline Compound (I) of claim 1 .
13. A crystalline Compound (I):
which has an X-ray powder diffraction pattern comprising peaks at 7.2, 17.4, 22.3, 22.4, 22.4, 28.9, 33.7, and 33.8±0.2° 2θ.
14. The crystalline Compound (I) of claim 13 , which has an X-ray powder diffraction pattern as shown in FIG. 12 .
15. The crystalline Compound (I) of claim 13 , wherein the crystalline Compound (I) comprises less than 10% by weight of any other crystalline Compound (I).
16. The crystalline Compound (I) of claim 15 , wherein the crystalline Compound (I) comprises less than 5% by weight of any other crystalline Compound (I).
17. The crystalline Compound (I) of claim 13 , wherein the crystalline Compound (I) comprises less than 10% by weight of amorphous Compound (I).
18. The crystalline Compound (I) of claim 17 , wherein the crystalline Compound (I) comprises less than 5% by weight of amorphous Compound (I).
19. The crystalline Compound (I) of claim 13 , wherein the crystalline Compound (I) comprises less than 100 ppm of a compound of Formula (II):
as determined by GC/MS.
20. The crystalline Compound (I) of claim 19 , wherein the crystalline Compound (I) comprises less than 50 ppm of a compound of Formula (II) as determined by GC/MS.
21. The crystalline Compound (I) of claim 13 , wherein the crystalline Compound (I) is at least 99.5% pure as measured by HPLC.
22. A pharmaceutical composition comprising a crystalline Compound (I) of claim 13 .
23. A method of treating anemia, comprising administering a pharmaceutical composition comprising an effective amount of a crystalline Compound (I) of claim 13 .